---
title: "Aumolertinib plus radiotherapy in EGFR‑mutant stage III NSCLC: Phase III ADVANCE trial and real‑wo"
id: "pubmed-42764281"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42764281"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42764281/"
doi: "10.1038/s41392-026-02891-2"
published_at: "2026-09-21T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Aumolertinib plus radiotherapy in EGFR‑mutant stage III NSCLC: Phase III ADVANCE trial and real‑wo
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42764281
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42764281/)
- **DOI:** [10.1038/s41392-026-02891-2](https://doi.org/10.1038%2Fs41392-026-02891-2)
- **Published At:** 2026-09-21T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The PubMed entry reports a Phase III clinical trial, named **ADVANCE**, investigating induction and concurrent **aumolertinib** with radiotherapy in patients with **EGFR‑mutated stage III NSCLC**. - The article is a clinical trial report published in Signal Transduct Target Ther on 21 September 2026 (Volume 11, Article 395) with DOI 10.1038/s41392-026-02891-2 and PMID 42764281. - Multiple Chinese radiation oncology centers and collaborators contributed; authors include Nan Bi, Jianyang Wang, Wei Jiang and many coauthors across institutions, with one coauthor from Johns Hopkins (Division of Quantitative Sciences). - The PubMed record identifies the study as a Clinical Trial and indicates the work includes both a randomized phase III trial component and a real‑world validation cohort. - The entry names the intervention strategy (induction and concurrent systemic **aumolertinib** with radiotherapy) and the target population (**EGFR‑mutated stage III NSCLC**). - The PubMed abstract text and full trial outcome measures (primary/secondary endpoints, efficacy data, safety profile, patient numbers, randomization details, statistical results) are not displayed in the provided source content. - Trial identifiers beyond PMID and DOI, sample sizes, efficacy endpoints (such as PFS/OS/locoregional control), toxicity grades, and numerical results were not reported in the accessible PubMed record. - Affiliations indicate a multi‑center Chinese investigator group with national cancer center leadership; the record notes equal contribution by several first authors. - Because outcome data and methodological details are not included in the provided PubMed content, readers should consult the full text (Signal Transduct Target Ther) for complete efficacy and safety results, trial design, and real‑world validation methods.
## Clinical Analysis & Structured Key Points
Signal transduction and targeted therapy clinical record · DOI 10.1038/s41392-026-02891-2
## Related Clinical Research

- [Investigation finds 20 unnecessary mastectomies at County Durham and Darlington trust](https://medichelpline.com/clinical-feed/bmj-2-mastectomy-scandal-twenty-women-had-unnecessary-procedure-at-trust.md)
- [Interpretable deep learning (TabNet) predicts early immune-related adverse events in hepatocellula](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-development-and-external-validation-of-an-interpretable-deep-learning-model-for.md)
- [EnBCDet: Explainable Contrastive Self-Supervised Model for Malignant Cell Detection in Urine Cytol](https://medichelpline.com/clinical-feed/pubmed-42765133.md) (DOI: 10.1088/2057-1976/aea429)
- [BCLXL blockade as strategy to overcome PARP inhibitor resistance in ovarian cancer](https://medichelpline.com/clinical-feed/pubmed-42764286.md) (DOI: 10.1038/s41392-026-02870-7)
- [Telix to Acquire ITM in $1.65B Radiopharmaceuticals Merger](https://medichelpline.com/clinical-feed/stat-news-8-stat-radiopharma-companies-merge-after-one-receives-surprise-fda-rejection.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.